This is a working overview of c-Met receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Also in 2012, the group of Juho Rousu at University of Helsinki, Finland, introduced a machine learning method to predict molecular properties from tandem MS data. This concept was brought together with the fragmentation tree concept in 2015 resulting in CSI:FingerID, being introduced in SIRIUS 3. The fragmentation tree is used to predict a molecular fingerprint of the unknown molecule using machine learning, which in turn is used to search a molecular structure database such as PubChem. Molecular structure databases are orders of magnitude larger than reference spectra libraries (PubChem containing ~111 million compounds in 2021 compared to NIST Tandem Mass Spectral Library containing ~50.000 compounds in 2023). This kind of structure identification refers to the identity and connectivity (with bond multiplicities) of the atoms, but not stereochemistry information. Elucidation of stereochemistry is currently beyond the power of automated search engines. SIRIUS 3 also introduced the graphical user interface (GUI). In 2020, in cooperation with the group of Pieter C Dorrestein at UC San Diego, USA, molecular formula identification was improved based on derivative networks from complete biological datasets to rank molecular formula candidates. This method is called ZODIAC and has been integrated into SIRIUS 4. Also in 2020, in cooperation with Rousu's and Dorrestein's groups, CANOPUS for systematic compound class annotation was introduced to SIRIUS 4.
The drag here is low enough that it could theoretically be overcome by radiation pressure on solar sails, a proposed propulsion system for interplanetary travel. All of the observable universe is filled with large numbers of photons, the so-called cosmic background radiation, and quite likely a correspondingly large number of neutrinos. The current temperature of this radiation is about 3 K (−270.15 °C; −454.27 °F).
Regarding the death of Henry King, Jr., Johns revealed that he always "had a finite story", going "from this almost unlikeable bully to possibly a redeemed hero, and then ultimately die protecting his new friends when facing his father, while also learning a lesson that Courtney imparted on him and apologizing to Yolanda". Johns spoke with actor Jake Austin Walker before he signed on to play the character to inform him of this and discuss the character with him. The character's return in the season one finale with his father pretending to be his son was done to subvert the "nobody ever dies" superhero trope. Yolanda Montez's struggle with killing Brainwave was "a big part of season 2". Johns added that compared to Rick Tyler, who is "starting to kind of turn a corner" after overcoming his anger for his parents' death, Yolanda is "turning the other way... She's lost in her own world, thinking about what she has done" since she was not ready to kill someone, unlike Rick. Additionally, more motivations from the surviving members of the Injustice Society are explored in the second season. Bassinger teased that the third season would feature a murder mystery.
Schabowski gave a confusing answer that asserted it was necessary because West Germany had exhausted its capacity to accept fleeing East Germans, then remembered the note he had been given and added that a new regulation had been drafted to allow permanent emigration at any border crossing. This caused a stir in the room; amid several questions at once, Schabowski expressed surprise that the reporters had not yet seen this regulation, and started reading from the note. After this, a reporter, either Ehrman or Bild-Zeitung reporter Peter Brinkmann, both of whom were sitting in the front row at the press conference, asked when the regulations would take effect. After a few seconds' hesitation, Schabowski replied, "As far as I know, it takes effect immediately, without delay" (German: Das tritt nach meiner Kenntnis ... ist das sofort ... unverzüglich). This was an apparent assumption based on the note's opening paragraph; as Beil attempted to interject that it was up to the Council of Ministers to decide when it took effect, Schabowski proceeded to read this clause, which stated it was in effect until a law on the matter was passed by the Volkskammer. Crucially, a journalist then asked if the regulation also applied to the crossings to West Berlin. Schabowski shrugged and read item 3 of the note, which confirmed that it did. After this exchange, Daniel Johnson of The Daily Telegraph asked what this law meant for the Berlin Wall. Schabowski sat frozen before giving a rambling statement about the Wall being tied to the larger disarmament question.
Sources: en.wikipedia.org
However, she cares deeply about Dee Dee and eventually blooms to care for Mona as well, often offering advice to the both of them. She has an on-going rivalry with Phyllis, although the two occasionally call a truce. Chico Benymon as Andre "Spencer" Williams. Mona's best friend and co-worker, whom she's known since college. The two briefly date throughout the series, but remain on good terms. Alec Mapa as Adam Benet. Mona's openly gay assistant who is very nosy and gossipy. He often hits on Spencer and insults Mona on her unfashionable appearance.
Deploying in the stratosphere ensures that the aerosols are at their most effective, and that the progress of clean air measures would not be reversed: more recent research estimated that even under the highest-emission scenario RCP 8.5, the addition of stratospheric sulfur required to avoid 4 °C (7.2 °F) relative to now (and 5 °C (9.0 °F) relative to the preindustrial) would be effectively offset by the future controls on tropospheric sulfate pollution, and the amount required would be even less for less drastic warming scenarios. This spurred a detailed look at its costs and benefits, but even with hundreds of studies into the subject completed by the early 2020s, some notable uncertainties remain.
Several major Big Boy franchisees accepted Marriott's offer and became Roy Rogers regional franchisees, including Abdow's, Frisch's, Elias Brothers, Marc's, and Shoney's which together covered much of the Northeastern, Midwest and Southern US. Pittsburgh franchisee Eat'n Park rejected the offer and took public offense at paying fees to Rogers. In the Pittsburgh area and elsewhere, other regional franchisees were sought who would also subfranchise to smaller operators, and by January 1969, Marriott claimed regional franchises for every state but Alaska. Roy Rogers' restaurants also opened in Canada, franchised to that nation's Big Boy franchisee, JB's of Canada. Marriott divided the United States into 33 franchise regions and required regional franchisees open a set number of restaurants in a four-year period. Regional franchisees would pay Marriott a 2% royalty, and subfranchisees typically pay the regional franchisee 3%, who would keep the additional 1%. A restaurant required a $35,000 cash investment upfront, including $7,500 paid to Marriott. Additionally, the cost of the building and equipment, with seating for 42 persons, cost about $100,000 in 1968, excluding the cost of land. Marriott offered financing but charged an interest rate of 12% on land and 17% for the building. The prototype restaurant seated 40 to 45 persons with additional outdoor seating on an optional patio in front of the building, but actual restaurants varied, one franchisee's dining area accommodating 75 persons.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.